Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Placenta-extracted heat shock protein preparation is a biologic therapeutic derived from human placental tissue, enriched for various heat shock proteins (HSPs) such as HSP70, HSP90, and gp96. Developed by Boao Evergrande International Hospital, this preparation is being investigated in pilot clinical studies for its immunomodulatory potential in treating autoimmune diseases, including ankylosing spondylitis, systemic lupus erythematosus, and rheumatoid arthritis. The mechanism involves the interaction of HSPs with antigen-presenting cells (APCs) via receptors like CD91 and Toll-like receptors (TLRs), which can lead to the modulation of T-cell responses and the induction of regulatory T cells (Tregs), potentially restoring immune tolerance and reducing systemic inflammation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on placenta-extracted heat shock protein preparation.